SEC Tracker
Get the app

Organon OGN

Carrie Smith Cox (OGN) Chief Financial Officer Jane Doe reported purchasing 25,000 shares of OGN stock for a total transaction value of $500,000. This insider buying activity signals a bullish sentiment from company leadership and suggests they believe the stock is currently undervalued.

Carrie Smith Cox, insider filing for OGN

Form
4
Filed
Importance
Routine

Open in the appGet the appView on EDGAR

Get an email when Organon files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cytokinetics CYTK public float $2.5B, Jun 30, 2025
  2. TG Therapeutics TGTX public float $2.5B, Jun 30, 2025
  3. Catalyst Pharmaceuticals CPRX public float $2.5B, Jun 30, 2025
  4. Summit Therapeutics SMMT public float $2.5B, Jun 30, 2025
  5. Xenon Pharmaceuticals XENE public float $2.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.